These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 19673650)

  • 41. Mutations in the core and NS5A region of hepatitis C virus genotype 1b and correlation with response to pegylated-interferon-alpha 2b and ribavirin combination therapy.
    Hayashi K; Katano Y; Ishigami M; Itoh A; Hirooka Y; Nakano I; Urano F; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Viral Hepat; 2011 Apr; 18(4):280-6. PubMed ID: 20367792
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Evidence of recombination in quasispecies populations of a Hepatitis C Virus patient undergoing anti-viral therapy.
    Moreno MP; Casane D; López L; Cristina J
    Virol J; 2006 Oct; 3():87. PubMed ID: 17062150
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Mutations in the NS5A and E2-PePHD region of hepatitis C virus type 1b and correlation with the response to combination therapy with interferon and ribavirin.
    Hung CH; Lee CM; Lu SN; Lee JF; Wang JH; Tung HD; Chen TM; Hu TH; Chen WJ; Changchien CS
    J Viral Hepat; 2003 Mar; 10(2):87-94. PubMed ID: 12614464
    [TBL] [Abstract][Full Text] [Related]  

  • 44. HIV/Hepatitis C virus-coinfected virologic responders to pegylated interferon and ribavirin therapy more frequently incur interferon-related adverse events than nonresponders do.
    Osinusi A; Rasimas JJ; Bishop R; Proschan M; McLaughlin M; Murphy A; Cortez KJ; Polis MA; Masur H; Rosenstein D; Kottilil S
    J Acquir Immune Defic Syndr; 2010 Mar; 53(3):357-63. PubMed ID: 20101190
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Mutations in non-structural 5A and rapid viral response to pegylated interferon-α-2b plus ribavirin therapy are associated with therapeutic efficacy in patients with genotype 1b chronic hepatitis C.
    Yano Y; Seo Y; Miki A; Saito M; Kato H; Hamano K; Oya M; Ouchi S; Fujisawa T; Yamada H; Yamashita Y; Tani S; Hirohata S; Yoon S; Kitajima N; Kitagaki K; Kawara A; Nakashima T; Yu H; Maeda T; Azuma T; El-Shamy A; Hotta H; Hayashi Y;
    Int J Mol Med; 2012 Nov; 30(5):1048-52. PubMed ID: 22899224
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Evolution of hepatitis C virus quasispecies during ribavirin and interferon-alpha-2b combination therapy and interferon-alpha-2b monotherapy.
    Arataki K; Kumada H; Toyota K; Ohishi W; Takahashi S; Tazuma S; Chayama K
    Intervirology; 2006; 49(6):352-61. PubMed ID: 16926548
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Longitudinal analysis of the 5'UTR, E2-PePHD and NS5A-PKRBD genomic regions of hepatitis C virus genotype 1a in association with the response to peginterferon and ribavirin therapy in HIV-coinfected patients.
    Bolcic F; Laufer N; Torres C; Cassino L; Reynoso R; Quarleri J
    Antiviral Res; 2012 Aug; 95(2):72-81. PubMed ID: 22683884
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Association of interleukin 28B polymorphism and mutations in the NS5A region of hepatitis C virus genotype 2 with interferon responsiveness.
    Hayashi K; Katano Y; Ishizu Y; Kuzuya T; Honda T; Ishigami M; Itoh A; Hirooka Y; Ishikawa T; Nakano I; Yoshioka K; Toyoda H; Kumada T; Goto H
    J Gastroenterol Hepatol; 2015 Jan; 30(1):178-83. PubMed ID: 24995561
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Dynamics of hepatitis C virus NS5A quasispecies during interferon and ribavirin therapy in responder and non-responder patients with genotype 1b chronic hepatitis C.
    Puig-Basagoiti F; Forns X; Furčić I; Ampurdanés S; Giménez-Barcons M; Franco S; Sánchez-Tapias JM; Saiz JC
    J Gen Virol; 2005 Apr; 86(Pt 4):1067-1075. PubMed ID: 15784900
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Sustained virologic response and IL28B single-nucleotide polymorphisms in patients with chronic hepatitis C treated with pegylated interferon alfa and ribavirin.
    Jabłonowska E; Piekarska A; Koślińska-Berkan E; Omulecka A; Szymańska B; Wójcik K
    Acta Biochim Pol; 2012; 59(3):333-7. PubMed ID: 22924160
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Mutations in the NS5A and E2-PePHD regions of hepatitis C virus genotype 1b and response to combination therapy of interferon plus ribavirin.
    Yang SS; Lai MY; Chen DS; Chen GH; Kao JH
    Liver Int; 2003 Dec; 23(6):426-33. PubMed ID: 14986817
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Viral kinetics in hepatitis C or hepatitis C/human immunodeficiency virus-infected patients.
    Sherman KE; Shire NJ; Rouster SD; Peters MG; James Koziel M; Chung RT; Horn PS
    Gastroenterology; 2005 Feb; 128(2):313-27. PubMed ID: 15685543
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Association between HCV amino acid substitutions and outcome of peginterferon and ribavirin combination therapy in HCV genotype 1b and high viral load.
    Toyoda H; Kumada T; Tada T; Arakawa T; Hayashi K; Honda T; Katano Y; Goto H
    J Gastroenterol Hepatol; 2010 Jun; 25(6):1072-8. PubMed ID: 20594221
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prospective characterization of full-length hepatitis C virus NS5A quasispecies during induction and combination antiviral therapy.
    Nousbaum J; Polyak SJ; Ray SC; Sullivan DG; Larson AM; Carithers RL; Gretch DR
    J Virol; 2000 Oct; 74(19):9028-38. PubMed ID: 10982347
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Daclatasvir plus peginterferon and ribavirin is noninferior to peginterferon and ribavirin alone, and reduces the duration of treatment for HCV genotype 2 or 3 infection.
    Dore GJ; Lawitz E; Hézode C; Shafran SD; Ramji A; Tatum HA; Taliani G; Tran A; Brunetto MR; Zaltron S; Strasser SI; Weis N; Ghesquiere W; Lee SS; Larrey D; Pol S; Harley H; George J; Fung SK; de Lédinghen V; Hagens P; McPhee F; Hernandez D; Cohen D; Cooney E; Noviello S; Hughes EA
    Gastroenterology; 2015 Feb; 148(2):355-366.e1. PubMed ID: 25311593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Polymorphisms of hepatitis C virus non-structural protein 5A and core protein and clinical outcome of pegylated-interferon/ribavirin combination therapy.
    El-Shamy A; Kim SR; Ide YH; Sasase N; Imoto S; Deng L; Shoji I; Hotta H
    Intervirology; 2012; 55(1):1-11. PubMed ID: 21293098
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Early and sustained virological response in non-responders with chronic hepatitis C: a randomized open-label study of pegylated interferon-alpha-2a versus pegylated interferon-alpha-2b.
    Scotto G; Fazio V; Fornabaio C; Tartaglia A; Di Tullio R; Saracino A; Angarano G
    Drugs; 2008; 68(6):791-801. PubMed ID: 18416586
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Distinct hepatitis C virus kinetics in HIV-infected patients treated with ribavirin plus either pegylated interferon alpha2a or alpha2b.
    Vispo E; Barreiro P; Rodriguez-Nóvoa S; Morello J; Labarga P; Martín-Carbonero L; Maida I; García-Gascó P; Soriano V
    Antivir Ther; 2008; 13(4):511-7. PubMed ID: 18672529
    [TBL] [Abstract][Full Text] [Related]  

  • 59. IL28B gene polymorphisms and viral kinetics in HIV/hepatitis C virus-coinfected patients treated with pegylated interferon and ribavirin.
    Rallón NI; Soriano V; Naggie S; Restrepo C; Goldstein D; Vispo E; McHutchison J; Benito JM
    AIDS; 2011 May; 25(8):1025-33. PubMed ID: 21505315
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Role of Hepatitis C Virus NS5A Region Mutation and SNP IL-28B of Host to Support Successful Pegylated Interferon and Ribavirin Treatment in Patients with HCV-HIV Coinfection: A Prospective Cohort Study.
    Kurniawan J; Gani RA; Djauzi S; Ibrahim F; Harimurti K; Nafrialdi N; Imannuel S
    Acta Med Indones; 2019 Apr; 51(2):128-136. PubMed ID: 31383827
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.